Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival by Morganti A.G. et al.
Morganti et al. BMC Cancer          (2019) 19:569 
https://doi.org/10.1186/s12885-019-5790-2RESEARCH ARTICLE Open AccessAdjuvant chemoradiation in pancreatic
cancer: impact of radiotherapy dose on
survival
Alessio G. Morganti1, Francesco Cellini2, Milly Buwenge1* , Alessandra Arcelli1, Sergio Alfieri3, Felipe A. Calvo4,
Riccardo Casadei5, Savino Cilla6, Francesco Deodato7, Giancarmine Di Gioia1, Mariacristina Di Marco8,
Lorenzo Fuccio5, Federica Bertini1, Alessandra Guido1, Joseph M. Herman9, Gabriella Macchia7,
Bert W. Maidment III10, Robert C. Miller11, Francesco Minni5, Paolo Passoni12, Chiara Valentini13, Alessia Re2,
William F. Regine14, Michele Reni12, Massimo Falconi15, Vincenzo Valentini2 and Gian Carlo Mattiucci2Abstract
Background: To evaluate the impact of radiation dose on overall survival (OS) in patients treated with adjuvant
chemoradiation (CRT) for pancreatic ductal adenocarcinoma (PDAC).
Methods: A multicenter retrospective analysis on 514 patients with PDAC (T1–4; N0–1; M0) treated with surgical
resection with macroscopically negative margins (R0–1) followed by adjuvant CRT was performed. Patients were
stratified into 4 groups based on radiotherapy doses (group 1: < 45 Gy, group 2: ≥ 45 and < 50 Gy, group 3: ≥ 50
and < 55 Gy, group 4: ≥ 55 Gy). Adjuvant chemotherapy was prescribed to 141 patients. Survival functions were
plotted using the Kaplan-Meier method and compared through the log-rank test.
Results: Median follow-up was 35 months (range: 3–120 months). At univariate analysis, a worse OS was recorded
in patients with higher preoperative Ca 19.9 levels (≥ 90 U/ml; p < 0.001), higher tumor grade (G3–4, p = 0.004), R1
resection (p = 0.004), higher pT stage (pT3–4, p = 0.002) and positive nodes (p < 0.001). Furthermore, patients
receiving increasing doses of CRT showed a significantly improved OS. In groups 1, 2, 3, and 4, median OS was 13.0
months, 21.0 months, 22.0 months, and 28.0 months, respectively (p = 0.004). The significant impact of higher dose
was confirmed by multivariate analysis.
Conclusions: Increasing doses of CRT seems to favorably impact on OS in adjuvant setting. The conflicting results
of randomized trials on adjuvant CRT in PDAC could be due to < 45 Gy dose generally used.
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Pancreatic carcinoma is projected to become the second
leading cause of cancer mortality by 2030 with a 5-year
overall survival (OS) rate around 7% [1]. At diagnosis,
around 20% of pancreatic cancer patients present with a
resectable tumor, 30% with a locally advanced tumor and
50% with metastatic disease [2]. Radical surgery with© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
* Correspondence: mbuwenge@gmail.com
1Radiation Oncology Center, Department of Experimental, Diagnostic and
Specialty Medicine-DIMES, University of Bologna, S. Orsola-Malpighi Hospital,
via Giuseppe Massarenti 9, 40138 Bologna, Italy
Full list of author information is available at the end of the articletumor-free margins is the only treatment with the poten-
tial to achieve long-term survival [3].
Nevertheless, both local or distant relapses commonly
affect patients’ survival [4]. Therefore, local and systemic
adjuvant treatments have been proposed to improve OS.
Many clinical trials evaluated the efficacy of adjuvant
chemo-radiotherapy (CRT) and chemotherapy (CT).
The efficacy of CT has been demonstrated [5–7] but the
potential impact of CRT in the adjuvant setting remains
controversial. In fact, an improved OS after postoperative
CRT was described in several reports including: random-
ized trials as the Gastrointestinal Tumor Study group
(GITSG) [8, 9] and European Organization for Researchle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Morganti et al. BMC Cancer          (2019) 19:569 Page 2 of 10and Treatment of Cancer (EORTC) [10, 11] trials, single
center analyses [12–14], meta-analyses [15] or pooled ana-
lyses [16, 17], and tumor registry studies [18–22].
On the other hand, the European Study Group for
Pancreatic Cancer-1 (ESPAC-1) trial reported negative
results after adjuvant CRT [5, 23, 24]. Characteristic of
this study was the prescription of a relatively low dose of
radiotherapy (RT) (40 Gy with split course regimen)
similar to the previous GITSG [8, 9] and EORTC [10,
11] trials. It could be hypothesized that this dose was in-
effective in improving local control (LC) of the disease
and ultimately OS as suggested by some studies [25]. In
fact, in the GITSG study, the incidence of local recur-
rence was 33% in patients who underwent surgery alone
and 49% in patients undergoing adjuvant CRT and CT
[9]. However, only few studies evaluated the impact of
postoperative CRT dose on clinical outcome [25, 26].
Our previous pooled analysis confirmed the positive
impact of adjuvant CRT on OS [27]. Therefore, on the
basis of the above considerations, a secondary analysis of
that study was performed in order to assess the impact
of CRT dose on clinical outcome in terms of OS. The
purpose of this paper is to report the results of this sec-
ondary analysis.Methods
Study design and participants
Clinical data from 7 different institutions (Baltimore [2
institutions], Rochester, Madrid, Rome, Campobasso,
Milan) were retrospectively pooled for this analysis on
individual patient basis. Treatment was delivered be-
tween 1995 and 2008.
The following exclusion criteria were used: metastatic
disease (M1), diagnoses different from pancreatic ductal
adenocarcinoma (PDAC), neoadjuvant treatment and/or
intraoperative radiation therapy, postoperative CRT dose
< 40 Gy, death within 60 days of surgery, and missing
data on pathological tumor (pT) stage and/or nodal sta-
tus. By excluding patients with missing data on survival
and/or not eligible, 955 patients remained in our refer-
ence database. In this analysis, only 514 patients receiv-
ing postoperative CRT (Fig. 1) were included.
The following variables were analyzed: gender, age, tumor
location (head, body, tail), tumor grade (I-IV), tumor diam-
eter (mm), surgical procedure (pancreaticoduodenectomy,
distal, total pancreatectomy), pT and nodal stage and pres-
ence of microscopic residual disease. Patients were stratified
into 4 classes based on RT doses (< 45Gy, ≥ 45 and < 50
Gy, ≥ 50 and < 55Gy, ≥ 55Gy).
The first cut-off of 45Gy was applied to discriminate pa-
tients treated with dosage similar to the most important
randomized trials [5, 8, 10]. The second cut-off of 50 Gy
represents the dosage recommended by internationalguidelines [28]. The third cut-off of 55Gy was selected be-
cause a substantial number of patients received higher
doses based on the personal experience of radiation oncol-
ogists, their technological equipment, and due to the
higher risk of local recurrence.
Adjuvant CRT
The details of adjuvant RT have been described in detail
elsewhere [13, 14, 17, 27, 29–31]. In brief, adjuvant
external-beam RT was delivered with linear accelerators on
tumor bed and regional nodes using multiple-field tech-
niques. CRT dose ranged between 40.0 and 61.2 Gy (me-
dian: 50.4 Gy). Most patients underwent 3D-conformal
therapy while no patient received treatment based on In-
tensity Modulated RT or Volumetric Arc Therapy. All pa-
tients received a continuous course of CRT without a
planned break. The dose was prescribed according to the
guidelines of International Commission on Radiation Units
Measurements Report 50. In most centers concurrent CT
was based on 5-fluorouracil or capecitabine and adjuvant
CT was mainly based on gemcitabine.
End-points
The primary end-point was OS calculated from the date
of diagnosis. Secondary aim was to investigate factors as-
sociated with OS.
Statistical analysis
Descriptive statistics included frequencies and percentages
for categorical variables and means plus standard devia-
tions or medians and range for continuous variables. Chi-
square Pearson analysis was used to determine any statis-
tical significance between the distributions of categorical
variables while Kruskal-Wallis test was undertaken to de-
termine any statistical significance for continuous variable.
Survival functions were plotted using the Kaplan-Meier
method [32] and compared through the log-rank test [33]
to investigate differences in OS between groups defined
based on clinical and pathological factors. Clinical and
pathological parameters associated with significant differ-
ences in OS at the univariate analysis were entered into a
multivariable Cox model using a forward stepwise [Wald]
strategy [34] (p removal ≥0.10; p addition < 0.05) based on
likelihood ratio test in order to obtain a final model in-
cluding only the subset of variables significant in predict-
ing OS. All tests were two-sided and a p value < 0.05 was
considered statistically significant. Statistical analysis was
performed with IBM SPSS (IBM SPSS Statistics for Win-
dows, Inc., Version 20.0; IBM Corp, Armonk, NY, USA).
Results
Median follow-up time was 35months (range: 3–120
months). The median age for the entire cohort of 514 pa-
tients was 63 years (range: 29–85 years). No differences
Fig. 1 Flow-chart of patients’ selection
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45 and < 50Gy, ≥ 50 and < 55Gy, ≥ 55 Gy) were observed
in terms of median age, mean tumor diameter and tumor
site while type of resection (p < 0.001), grading (p < 0.001),
rate of R1 resection (p = 0.032), tumor stage (p = 0.006),
incidence of lymph nodes involvement (p = 0.001), and ad-
juvant CT treatment (p < 0.001) were different between
the groups. In particular, the cohort of patients whoreceived a dose ≥ 55 Gy differed significantly from the
other groups both for more unfavourable prognostic char-
acteristics (higher percentage of patients with positive
margins, with tumor diameter ≥ 30mm, with pT4 and
pN+ stage) and for an increased use of adjuvant CT
(Table 1). Concurrent CT was based on 5-FU regimen
in 71.6% of patients, while 28.4% of patients were
treated with different regimens: gemcitabine (14.4%),
Table 1 Patients characteristics: number [No] and percentages [%] of patients
Variable Value No of
patients
[%]
No of patients [%]
treated with < 45 Gy
No of patients [%] treated
with ≥ 45 and < 50 Gy
No of patients [%] treated
with ≥ 50 and < 55 Gy
No of patients [%]
treated with ≥ 55 Gy
p value
Age Median
(range)
63.0 (29–
85)
64.4 (38–81) 64.0 (41–84) 63.9 (29–86) 62.0 (35–78) .479
Tumor
diameter
(cm)
Mean
(SD)
2.82 ± 1.51 2.95 ± 1.48 3.12 ± 1.42 3.00 ± 1.31 .190
Gender Male 239 [46.5] 11 [42.3] 31 [43.1] 156 [47.0] 41 [48.8] .410
Female 275 [53.5] 15 [57.7] 41 [56.9] 176 [53.0] 43 [51.2]
Ca 19.9
(units/mL)
< 90 114 [22.1] 5 [19.2] 21 [29.2] 67 [20.2] 21 [25.0]. .076
≥ 90 137 [26.7] 4 [15.4] 16 [22.2] 83 [25.0] 34 [40.5]
Unknown 263 [51.2] 17 [65.4] 35 [48.6] 182 [54.8] 29 [34.5]
Tumor site Head 432 [84.0] 22 [84.6] 66 [91.6] 272 [81.9] 72 [85.7] .408
Body 26 [5.1] 2 [7.7] 1 [1.4] 17 [5.1] 6 [7.1]
Tail 36 [7.0] 2 [7.7] 2 [2.8] 27 [8.2] 5 [6.0]
Unknown 20 [3.9] 0 [0.0] 3 [4.2] 16 [4.8] 1 [1.2]
Type of
resection
DCP 315 [61.2] 14 [53.8] 41 [56.9] 190 [57.2] 70 [83.3] <.001
DP 61 [11.9] 3 [11.6] 4 [5.6] 43 [13.0] 11 [13.1]
TP 21 [4.1] 4 [15.4] 4 [5.6] 12 [3.6] 1 [1.2]
PPP 117 [22.8] 5 [19.2] 23 [31.9] 87 [26.2] 2 [2.4]
Grading 1 34 [6.6] 1 [3.8] 5 [7.0] 12 [3.6] 16 [19.0] <.001
2 119 [23.2] 5 [19.2] 18 [25.0] 65 [19.6] 31 [36.9]
3 250 [48.6] 13 [50.0] 38 [52.7] 171 [51.5] 28 [33.3]
4 45 [8.8] 1 [3.8] 6 [8.3] 35 [10.5] 3 [3.6]
Unknown 66 [12.8] 6 [23.2] 5 [7.0] 49 [14.8] 6 [7.2]
Margins
status
R0 132 [25.7] 8 [30.8] 14 [19.4] 70 [21.1] 40 [47.6] .032
R1 61 [11.9] 3 [11.5] 4 [5.6] 22 [6.6] 32 [38.1]
Unknown 321 [62.4] 15 [57.7] 54 [75.0] 240 [72.3] 12 [14.3]
Tumor
diameter
< 30mm 68 [13.2] 5 [19.2] 9 [12.5] 17 [5.1] 37 [44.0] .206
≥ 30mm 61 [11.9] 2 [7.7] 4 [5.6] 24 [7.2] 31 [36.9]
Unknown 385 [74.9] 19 [73.1] 59 [81.9] 291 [87.7] 16 [19.1]
pT-stage 1 33 [6.4] 1 [3.8] 5 [6.9] 26 [7.9] 1 [1.2] .006
2 107 [20.8] 4 [15.4] 15 [20.8] 81 [24.4] 7 [8.3]
3 341 [66.3] 21 [80.8] 48 [66.7] 206 [62.0] 66 [78.6]
4 33 [6.4] 0 [0.0] 4 [5.6] 19 [5.7] 10 [11.9]
pN-stage N0 205 [39.9] 9 [34.6] 28 [38.9] 150 [45.2] 18 [21.4] .001
N+ 309 [60.1] 17 [65.4] 44 [61.1] 182 [54.8] 66 [78.6]
Adjuvant
CT
No 308 [59.9] 19 [73.1] 48 [66.7] 227 [68.4] 14 [16.7] <.001
Yes 141 [27.5] 3 [11.5] 18 [25.0] 54 [16.2] 66 [78.6]
Unknown 65 [12.6] 4 [15.4] 6 [8.3] 51 [15.4] 4 [4.7]
DCP duodenocephalopancreasectomy, DP distal pancreatectomy, TP total pancreatectomy, PPP pylorus preserving pancreatectomy, CT chemotherapy
Morganti et al. BMC Cancer          (2019) 19:569 Page 4 of 10capecitabine (9.5%), gemcitabine + 5-FU (3.1%) and
tegafur (1.4%). All patients who underwent adjuvant
CT were treated with gemcitabine.Overall survival
Patients receiving increasing doses of CRT showed a sig-
nificantly improved OS (Fig. 2). Median OS was 13.0
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dose, versus 21.0 months (95% CI, 16.6–25.3 months)
with ≥ 45 and < 50 Gy CRT dose, versus 22.0 months
(95% CI, 19.6–24.3 months) with ≥ 50 and < 55 Gy CRT
dose, versus 28.0 months (95% CI, 24.1–31.8 months)
with ≥ 55 Gy CRT dose (p = 0.004).
A better prognosis was recorded in patients with pre-
operative Ca 19.9 level < 90U/ml, lower tumor grade, R0
resection, lower pT stage, negative lymph nodes and who
received adjuvant CT. Table 2 shows survival differences
at univariate analysis based on clinical, pathological and
treatment details in the whole population.
To assess the impact of the different CRT dose on OS in
patients’ subsets, patients were stratified in subgroups based
on potentially predictive variables. The positive impact of
higher doses was confirmed with statistical significance in
female patients, both lower and higher Ca 19.9 subgroups,
in patients with PDAC of the pancreatic head, in patients
treated with duodenocephalopancreatectomy and total pan-
createctomy, in grade 1 and 3 PDAC, in both patients’
groups with negative and positive resection margins, in tu-
mors < 30mm diameter, in patients with pT3 and pN0 can-
cer, and receiving adjuvant CT (Table 3).
The delivery of higher RT doses resulted as a significant
predictor of OS also at multivariate analysis (Table 4). Our
multivariable model confirmed a better prognosis in pa-
tients treated with doses ≥ 45Gy. Comparing patients re-
ceiving < 45Gy with those receiving doses ≥ 45Gy and <Fig. 2 Overall survival of patients who received a chemo-radiation dose <50Gy (HR: 0.56, 95%CI: 0.34–0.92, p = 0.022), or those re-
ceiving doses ≥ 50Gy and < 55Gy (HR: 0.58, 95%CI: 0.38–
0.88, p = 0.012), or those receiving doses ≥ 55 Gy (HR:
0.45, 95%CI: 0.28–0.72, p < 0.001), a survival improvement
was recorded. Furthermore, a higher risk of mortality was
observed at multivariate analysis in patients with nodal in-
volvement (HR: 1.56; 95%CI: 1.25–1.95, p < 0.001). The
other parameters that significantly correlated with OS at
univariate analysis did not show a significant correlation
at multivariable analysis.
Moreover, considering that patients were treated over a
fairly long period of time in which the evolution of im-
aging techniques could have penalized patients treated in
an earlier period, we divided them into 4 groups based on
the year of resection: 1995–1998 (54 patients), 1999–2002
(89 patients), 2003–2005 (187 patients), and 2006–2008
(184 patients) and we analysed the correlation between
treatment period and administered dose and survival. In
the 4 groups, the mean postoperative RT dose underwent a
slight but statistically significant increase (50.6 +/− 4.9 Gy,
50.0 +/− 3.2 Gy, 51.2 +/− 3.9 Gy, 52.6 +/− 4.9 Gy, respect-
ively; p < 0.001). Furthermore, OS was also significantly im-
proved in patients treated in more recent periods. Indeed,
in the 4 groups, median survival was 14, 20, 26, and 24
months, respectively (p: 0.034). However, also this differ-
ence was not confirmed at multivariate analysis.
Furthermore, to assess more specifically whether doses
higher compared to doses now considered as standard45 Gy, or≥ 45 Gy or < 50 Gy, or≥ 50 Gy and < 55 Gy, or ≥ 55 Gy
Table 2 Univariate analysis including 2-, 5-year, and median overall survival (OS) time
Variable Value No. of patients 2-year OS (%) 5-year OS (%) Median OS (months) P value
Gender Male 239 50.0 23.8 25 .084
Female 275 43.1 18.0 21
Ca 19.9 (units/mL) < 90 114 62.6 31.5 32 .000
≥ 90 137 39.8 18.4 21
Tumor Site Head 432 47.0 20.9 23 .909
Body 26 40.4 11.8 21
Tail 36 44.3 15.8 22
Type of resection DCP 315 48.1 22.9 23 .090
DP 61 45.1 17.4 22
TP 21 20.8 10.4 16
PPP 117 47.0 18.0 22
Grading 1 34 61.8 39.2 29 .004
2 119 51.9 19.3 25
3 250 43.7 19.3 20
4 45 35.1 19.3 15
Margins status R0 132 59.7 25.2 29 .004
R1 61 36.8 10.8 20
Tumor diameter (mm) < 30 68 57.7 15.5 28 .529
≥ 30 61 48.4 20.3 24
pT-stage 1 33 70.3 41.9 45 .002
2 107 54.4 26.3 28
3 341 42.7 17.5 21
4 33 33.3 14.5 18
pN-stage N0 205 56.6 30.3 30 .000
N+ 309 39.6 14.4 20
Adjuvant CT No 308 43.1 21.1 20 .004
Yes 141 53.7 18.8 26
RT dose (Gy) < 45 26 24.0 4.0 13 .004
≥ 45 and < 50 72 44.6 25.1 21
≥ 50 and < 55 332 44.9 22.0 22
≥ 55 84 59.5 18.4 28
CT chemotherapy, DCP duodenocephalopancreatectomy, DP distal pancreatectomy, OS overall survival, PPP pylorus preserving pancreatectomy, RT radiotherapy,
TP total pancreatectomy
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and multivariate analysis including only the two sub-
groups of 50–55 Gy and > 55 Gy. Univariate analysis con-
firmed the advantage in the cohort receiving > 55 Gy
compared to patients treated with 50–55 Gy (2-year OS:
60.0% vs 45.0%, respectively; p: 0.033). Multivariate ana-
lysis, considering the group > 55 as a reference, con-
firmed a trend in terms of higher risk of death in the
50–55 Gy group (HR: 1.31; 95%CI: 0.98–1.74; p: 0.066).
Discussion
The main result of our study is that increasing RT doses is
significantly associated with an improved OS after resectionfor PDCA with radical intent. This finding has important
clinical consequences as well our study clearly shows that
postoperative RT dose higher than 45Gy should be pre-
scribed due to its association with significantly improved
prognosis. In addition, our study raises doubts about the
dose (50Gy) recommended by international guidelines [28]
especially for patients presenting negative prognostic fac-
tors at diagnosis (e.g., high Ca 19–9 level, R1 margin of re-
section, larger than 3 cm mass). In fact, our results
suggest that higher doses (≥ 55 Gy) should be consid-
ered when feasible.
We should admit that the comparison in terms of sur-
vival, including only the two groups treated with the
Table 3 Sub analysis of all predictor values of 2-, 5-year, and median overall survival (OS). Data are stratified for postoperative
chemo-radiation dose (< 45 Gy, > 45 and 50 Gy, ≥ 50 and < 55 Gy, ≥ 55 Gy)
Variable Value OS Median OS (months) p
value2-y (%) 5-y (%)
RT dose (Gy) < 45 ≥ 45 and <
50
≥ 50 and <
55
≥ 55 <
45
≥ 45 and <
50
≥ 50 and <
55
≥
55
<
45
≥ 45 and <
50
≥ 50 and <
55
≥
55
OS 24.0 44.6 44.9 59.5 4.0 25.1 22.0 18.4 13 21 22 28
Gender Male 45.5 43.8 49.3 58.5 9.1 33.4 22.7 27.4 20 22 24 28 .450
Female 7.1 45.5 41.1 60.5 0.0 20.0 21.3 10.5 11 21 21 29 <.001
Ca 19.9 (units/
mL)
< 90 0.0 61.5 60.3 81.0 0.0 39.1 38.3 10.3 8 3 35 31 <.001
≥ 90 0.0 9.2 37.2 61.8 0.0 0.0 15.8 32.7 12 18 19 27 .001
Tumor Site Head 23.8 40.7 46.3 61.1 0.0 22.0 23.1 20.5 13 20 23 28 .001
Body 0.0 0.0 38.2 66.7 0.0 0.0 20.4 0.0 11 17 23 38 .258
Tail 50.0 100.0 40.3 40.0 0.0 – 11.9 0.0 – – – – .406
Type of
resection
DCP 30.8 42.2 45.2 61.4 0.0 28.5 25.8 19.3 11 20 23 28 .016
DP 33.3 75.0 40.5 54.5 33.3 75.0 14.6 0.0 20 NR 22 38 .339
TP 0.0 25.0 19.4 – 0.0 25.0 0.0 – NR NR NR NR <.001
PPP 20.0 47.7 49.9 – 0.0 15.9 20.6 – 16 22 24 19 .666
Grading 1 – 20.0 66.7 75.0 – 20.0 41.7 45.5 7 21 33 38 <.001
2 80.0 57.7 45.0 58.1 20.0 42.7 18.4 0.0 30 44 23 28 .313
3 15.4 40.0 44.5 57.1 – 20.1 21.2 18.7 13 19 21 27 .039
4 – 50.0 33.6 33.3 – – 24.0 – 11 10 15 19 .622
Margins status R0 28.6 51.9 52.9 77.5 14.3 51.9 21.4 25.3 11 NR 25 32 .004
R1 – – 24.7 50.0 – – 12.3 10.7 10 9 20 24 <.001
Tumor
diameter
< 30
mm
20.0 25.9 50.0 73.0 – 25.9 0.0 21.3 7 22 23 31 <.001
≥ 30
mm
50.0 37.5 37.5 58.1 50.0 – 19.4 17.9 11 21 21 28 .493
pT-stage 1 100.0 75.0 66.9 100.0 – 75.0 40.1 0.0 30 NR 35 60 .320
2 50.0 66.7 53.2 42.9 25.0 35.0 25.5 21.4 11 49 25 19 .639
3 15.0 38.7 39.6 62.1 0.0 18.5 18.5 20.9 12 17 21 29 <.001
4 – 0.0 31.6 50.0 – – 15.8 15.0 NR 20 14 24 .263
pN-stage N0 25.0 64.9 53.4 83.3 0.0 35.7 29.8 42.3 10 36 27 49 <.001
N+ 23.5 32.4 37.7 53.0 5.9 18.9 15.6 11.4 16 18 20 25 .063
Adjuvant CT No 31.6 47.7 44.0 28.6 5.3 24.0 22.5 14.3 16 21 21 14 .105
Yes – 24.4 47.5 66.7 – 24.4 17.6 20.0 10 17 23 30 <.001
CT chemotherapy, DCP duodenocephalopancreatectomy, NR not reached, PPP pylorus preserving pancreatectomy, RT radiotherapy, TP total
pancreatectomy, DP distal pancreatectomy
Table 4 Multivariable analysis
Variable HR CI 95% p Value
pN0 1.00 (Ref.)
pN1 1.56 1.25–1.95 <.001
Postoperative RT < 45 Gy 1.00 (Ref.)
Postoperative RT≥ 45 and < 50 Gy 0.56 0.34–0.92 .022
Postoperative RT≥ 50 and < 55 Gy 0.58 0.38–0.88 .012
Postoperative RT≥ 55 Gy 0.45 0.28–0.72 <.001
RT radiotherapy
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cally significant improvement in the second group at uni-
variate analysis but with only a trend at multivariate
analysis. However, it should be noted that the possibility
of detecting a statistically significant difference was limited
by the presence in the first group of 79/336 (23.5%) pa-
tients receiving a dose of 54.0–55.0 Gy and in the second
group of 6/80 patients (7.5%) receiving a dose < 56Gy. In
other words, more than 30% of the patients included in
this sub-analysis received a dose between 54 and 56Gy,
practically equivalent from the clinical point of view.
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PDAC in the adjuvant setting. The use of postoperative
CRT in resected PDAC was initially founded on the re-
sults from the GITSG trial which demonstrated an im-
proved survival in patients treated with adjuvant CRT
and CT [8]. The results from this trial were confirmed
by the non-random enlargement of the sample size with
30 patients in the postoperative CRT arm [9]. That study
received some criticism mostly about its small sample
size (n = 51) and low dose of RT delivered with the obso-
lete approach of a split-course regimen.
The use of a low dose was justified by the fact that in
1973 when the protocol was designed, the criteria for
RT quality assurance were not developed and RT was
delivered with supervoltage equipment and anterior-
posterior/posterior-anterior fields. Unfortunately, al-
though the technological improvement could have
allowed the use of higher doses, in subsequent studies
the same RT regimen was used [5, 10].
Few analyses were previously published on the impact
of dose in the adjuvant CRT of PDAC. In an analysis of
patients with PDAC receiving postoperative CRT with 2
different dose levels, Abrams and colleagues did not ob-
serve a significantly different survival between patients
undergoing lower dose (50.4 Gy: median survival: 14.4
months) and patients receiving a higher dose (57.6 Gy:
median survival: 16.9 months) [26]. However, it should
be noted that in their analysis only 23 patients with
resected PDAC were included.
More recently, Hall and coworkers analyzed 1385 pa-
tients with PDAC treated with postoperative RT +/− CT.
Patients receiving a dose of 50–55Gy showed a signifi-
cantly higher survival compared to patients receiving doses
< 40Gy, 40 to < 50Gy, and doses > 55Gy. They concluded
that, on the basis of these results, the optimal dose of adju-
vant CRT should range between 50Gy and 55Gy [25].
The results of our study differ from those of the Hall’s
analysis with regard to patients treated with doses > 55
Gy. In fact, the survival of these patients was significantly
improved and worsened in our analysis and in that of Hall
and colleagues, respectively. The authors of the cited
study hypothesized that patients who underwent higher
doses were at least in part those with greater suspicion
(for example on CT-simulation) of residual macroscopic
disease or that lower survival was due to more serious
toxic effects after high-dose RT. The reasons for the
opposite result we observed may be due to the following
reasons: i) our study involved patients treated in a small
number of centers (all academic and research centers with
extensive experience in the treatment of PDAC) while the
analysis of Hall et al. was performed on data from the Na-
tional Cancer Data Base and only about one third of the
patients had been treated in academic/research cancer
programs facilities; ii) all patients included in the Hall’sstudy were treated from 1998 to 2002, while 72.2% of our
patients were treated later when the experience in treating
PDAC patients with conformal radiotherapy techniques
was probably improved.
Moreover, a significant impact of CRT dose on OS
was recorded and confirmed by multivariate analysis.
From the analysis we excluded patients who had re-
ceived a dose < 40 Gy. In fact, we hypothesized that the
delivery of doses < 40 Gy was likely due to disease pro-
gression in the course of CRT.
This study has obvious limitations, in particular the retro-
spective nature and the lack of data regarding some param-
eters (Table 1). Moreover, even if the total number of
analyzed patients is 514, only 26 patients received a dose <
45Gy. This low number may explain the lack of difference
in survival in some subgroups of patients (Table 3).
How the different disease (higher T and N stage, higher
rate of R1 resection, larger tumors) and treatment
(increased use of CT) characteristics in the group treated
with > 55Gy influenced the final result of the analysis is not
easy to interpret. However, it should be emphasized that in
the multivariate analysis, the lymph node involvement was
statistically correlated to survival while the same did not
happen for adjuvant CT. Therefore, as a whole, it is not
possible to state that this subgroup of patients presented
more favourable characteristics compared to others.
This result in some way allows us to better interpret
the conflicting results of published studies. In fact, in
studies showing an improved survival with the use of ad-
juvant CRT, doses of 50–50.4 Gy were used [13, 14]. In
contrast, the randomized EORTC [10] and ESPAC-1 [5]
trials showed lack or a negative impact of CRT with a
dose of 40 Gy.
The results of this analysis confirm the ineffectiveness
of low doses in improving the clinical outcome and jus-
tify the use of higher doses of RT in future studies on
adjuvant CRT. The use of higher doses seems feasible as
suggested by the acceptable toxicity reported in some
studies using doses > 50 Gy [30, 31]. Furthermore, with
the use of conformal techniques (3D-conformal or in-
tensity modulated RT), it is possible to administer even
higher doses or to intensify the treatment with acceler-
ated regimens. For example, in a dose escalation study
based on the 3D-conformal technique with a concomi-
tant boost on the tumor bed, a dose of 55 Gy was
reached with a slightly accelerated fractionation (2.2 Gy/
fraction) and with concurrent capecitabine. Although
this regimen is equivalent to a dose of 57.2 Gy in 2 Gy/
fraction (α/β ratio: 3) and despite the administration of
two cycles of gemcitabine before CRT, no patient
showed grade > 2 toxicity [35]. In addition, it was ob-
served that the use of intensity modulated RT allows a
reduction of the radiation dose to healthy organs [36]
without an increased incidence of local recurrence [37].
Morganti et al. BMC Cancer          (2019) 19:569 Page 9 of 10However, higher than standard doses should be pre-
scribed with caution in patients previously treated with
neoadjuvant or adjuvant multiple-drug CT, being the
impact of intensified systemic treatments on tolerance to
subsequent CRT not known.
Finally, based on the inefficiency of low CRT dose in
the adjuvant setting, the results of randomized trials
should not be further considered as those achievable
with modern RT. On the contrary, even in the meta-
analysis of Liao and colleagues, data from GITSG,
EORTC and ESPAC-1 trials were included [38].
Conclusion
In a secondary analysis from a retrospective study of pa-
tients who underwent radical pancreatectomy, there was
a significant relationship between RT dose and OS. This
result should lead to reconsider the role and doses of
postoperative CRT at least in some categories of patients
with higher risk of local recurrence. In addition, based
on the current availability of new and more effective sys-
temic therapies, further studies seem justified in order to
define the optimal integrated adjuvant therapies and in
particular their best sequence.
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